| CMX001Broad spectrum antiviral drug |
Sample solution is provided at 25 µL, 10mM.
Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.Nature.2018 Jun 13.Nature.2018 Jun 27.Nature.2018 Mar 29;555(7698):673-677.Nature.2017 Sep 7;549(7670):96-100.Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8Nat Nanotechnol.2017 Dec;12(12):1190-1198.Nature Biotechnology.2017 Jun;35(6):569-576Nat Med.2018 Sep 17.Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.Cell.Available online 25 October 2018.Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.Cell.2018 Jun 28;174(1):172-186.e21.Cell.2018 Feb 22;172(5):1007-1021.e17.Cell.2017 Nov 30;171(6):1284-1300.e21.Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.Cell.2017 Jul 13;170(2):312-323Nat Med.2018 Jan 29.Nat Med.2017 Nov;23(11):1342-1351.Cell.2017 Apr 6;169(2):286-300.Cell.2015 Aug 27;162(5):987-1002.Cell.2015 Feb 12;160(4):729-44.Nature Medicine.2017 Apr;23(4):493-500.Cancer Cell.2018 May 14;33(5):905-921.e5.Cancer Cell.2018 Apr 9;33(4):752-769.e8.Cancer Cell.2018 Mar 12;33(3):401-416.e8.Cancer Cell.2017 Aug 14;32(2):253-267.e5.Nat Methods.2018 Jul;15(7):523-526.Cell Stem Cell.2018 May 3;22(5):769-778.e4.Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.Quality Control & MSDS
- View current batch:
- Purity = 99.48%
- COA (Certificate Of Analysis)
- HPLC (Retest)
- MS (Mass Spectrometry)
- NMR (Nuclear Magnetic Resonance)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
| Cell experiment [1]: | |
Cell lines | Human fetal brain SVG cells |
Preparation method | The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition | 0.01, 0.03, 0.07, 0.1, and 1 μM, 96 h |
Applications | CMX001 caused a dose-dependent decrease in the number of JCV-infected cells during initial infection. In addition, CMX001 treatment resulted in a dose-dependent decrease in the number of JCV genome copies present in infected cells. |
| Animal experiment [2]: | |
Animal models | 4-6 week-old female A/Ncr mice |
Dosage form | Oral administration, 10 mg/kg on day 0 and 2.5 mg/kg every other-day |
Application | Treating mice with CMX001 at a 10 mg/kg dose followed by 2.5 mg/kg doses every other-day for two weeks provided solid protection against mortality and weight loss following an intra-nasal challenge of ectromelia virus. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1]. Jiang Z G, Cohen J, Marshall L J, et al. Hexadecyloxypropyl-cidofovir (CMX001) suppresses JC virus replication in human fetal brain SVG cell cultures[J]. Antimicrobial agents and chemotherapy, 2010, 54(11): 4723-4732. [2]. Parker S, Touchette E, Oberle C, et al. Efficacy of therapeutic intervention with an oral ether–lipid analogue of cidofovir (CMX001) in a lethal mousepox model[J]. Antiviral research, 2008, 77(1): 39-49. | |
CMX001 Dilution Calculator
calculate
CMX001 Molarity Calculator
calculate
| Cas No. | 444805-28-1 | SDF | Download SDF |
| Synonyms | N/A | ||
| Chemical Name | [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethyl-(3-hexadecoxypropoxy)phosphinic acid | ||
| Canonical SMILES | CCCCCCCCCCCCCCCCOCCCOP(=O)(COC(CN1C=CC(=NC1=O)N)CO)O | ||
| Formula | C27H52N3O7P | M.Wt | 561.69 |
| Solubility | <1.12mg l="" in="" dmso,="" limited="" solubility="" in="" etoh=""> | Storage | Store at -20°C |
| Physical Appearance | A solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
CMX001 is a broad spectrum antiviral agent [1].
CMX001 has been reported to be active in vitro against a broad range of viruses from all five families of dsDNA viruses infecting human with EC50 values of 0.02μM, 0.0004μM, 17μM , 0.045μM and 0.07μM for Adenovirus, Herpesvirus, Papillomavirus, Polyomavirus and Orthopoxvirus, respectively. In addition, CMX001 has been revealed to arrest disease progression by inhibiting viral DNA replication and thereby reducing viral burden. Apart from these, initial studies has been demonstrated the efficacy of CMX001 for pre-exposure and post-exposure prophylaxis in mouse, rabbit, cynomolgus monkeys and human [1].
References:[1]Lanier R1, Trost L, Tippin T, Lampert B, Robertson A, Foster S, Rose M, Painter W, O"Mahony R, Almond M, Painter G.Development of CMX001 for the Treatment of Poxvirus Infections. Viruses. 2010 Dec; 2(12):2740-2762.
